News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valens Pharma Ltd. Reports Top-line Results from Voluntary Phase II Trial



7/28/2008 2:43:50 PM

EDMONTON, July 28 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as "CardioMetabolics Inc."), today announced preliminary results from its voluntary Phase II "Mini-Metr(*)ics" clinical trial evaluating its proprietary intravenous formulation of dichloroacetate (DCA i.v.) in high risk, geriatric patients undergoing open heart surgical procedures. A primary objective of this exploratory Phase II study was to collect key information to help design further trials. A secondary objective was to determine if there was evidence of clinical efficacy for endpoints that included reduced time in the Intensive Care Unit for this patient group. Evidence of efficacy for those endpoints was not revealed in this pilot study. However, as expected, the biochemical benefits of DCA shown in earlier trials, such as lower plasma lactate levels and lower, more stable levels of glucose, were confirmed among treated patients.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES